Mayo Clinic Proceedings, ISSN 0025-6196, 2010, Volume 85, Issue 9, pp. 824 - 833
Waldenström macroglobulinemia is a B-cell malignancy with lymphoplasmacytic infiltration in the bone marrow or lymphatic tissue and a monoclonal immunoglobulin...
Internal Medicine | CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | PROGNOSTIC SCORING SYSTEM | MEDICINE, GENERAL & INTERNAL | ANTI-CD20 MONOCLONAL-ANTIBODY | HIGH-DOSE THERAPY | UNDETERMINED SIGNIFICANCE | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | STEM-CELL TRANSPLANTATION | COOPERATIVE-ONCOLOGY-GROUP | Recurrence | Waldenstrom Macroglobulinemia - blood | Antibodies, Monoclonal, Murine-Derived | Prognosis | Blood Viscosity | Waldenstrom Macroglobulinemia - therapy | Humans | Risk Factors | Rituximab | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Plasmapheresis | Waldenstrom Macroglobulinemia - drug therapy | Time Factors | Drug Therapy, Combination | Waldenstrom Macroglobulinemia - diagnosis | Immunologic Factors - therapeutic use | Care and treatment | Diagnosis | Anemia | Macroglobulinemia | Special
Internal Medicine | CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | PROGNOSTIC SCORING SYSTEM | MEDICINE, GENERAL & INTERNAL | ANTI-CD20 MONOCLONAL-ANTIBODY | HIGH-DOSE THERAPY | UNDETERMINED SIGNIFICANCE | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | STEM-CELL TRANSPLANTATION | COOPERATIVE-ONCOLOGY-GROUP | Recurrence | Waldenstrom Macroglobulinemia - blood | Antibodies, Monoclonal, Murine-Derived | Prognosis | Blood Viscosity | Waldenstrom Macroglobulinemia - therapy | Humans | Risk Factors | Rituximab | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Plasmapheresis | Waldenstrom Macroglobulinemia - drug therapy | Time Factors | Drug Therapy, Combination | Waldenstrom Macroglobulinemia - diagnosis | Immunologic Factors - therapeutic use | Care and treatment | Diagnosis | Anemia | Macroglobulinemia | Special
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2008, Volume 83, Issue 10, pp. 1131 - 1135
We report on the feasibility of outpatient transplant in 716 patients undergoing autologous stem cell transplant for multiple myeloma at Mayo Clinic's site in...
Internal Medicine | MEDICINE, GENERAL & INTERNAL | COST | THERAPY | MALIGNANCIES | LYMPHOMA | EXPERIENCE | ANTIMICROBIAL RESISTANCE | Survival Rate - trends | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Transplantation, Autologous | Quality Assurance, Health Care | Feasibility Studies | Minnesota - epidemiology | Stem Cell Transplantation - methods | Time Factors | Ambulatory Surgical Procedures - methods | Female | Aged | Retrospective Studies | Multiple Myeloma - surgery | Usage | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Autographs
Internal Medicine | MEDICINE, GENERAL & INTERNAL | COST | THERAPY | MALIGNANCIES | LYMPHOMA | EXPERIENCE | ANTIMICROBIAL RESISTANCE | Survival Rate - trends | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Transplantation, Autologous | Quality Assurance, Health Care | Feasibility Studies | Minnesota - epidemiology | Stem Cell Transplantation - methods | Time Factors | Ambulatory Surgical Procedures - methods | Female | Aged | Retrospective Studies | Multiple Myeloma - surgery | Usage | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Transplantation | Autographs
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S50 - S51
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 2, pp. S140 - S140
Journal Article
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2015, Volume 15, pp. S225 - S226
Journal Article
Science, ISSN 0036-8075, 10/2005, Volume 310, Issue 5745, pp. 96 - 100
Most people hold beliefs about personality characteristics typical of members of their own and others' cultures. These perceptions of national character may be...
National character studies | Personality traits | Sharks | Southeast Asian culture | Reports | Catholic schools | Slavic culture | Stereotypes | Irish culture | Universities | Personality psychology | STEREOTYPES | MULTIDISCIPLINARY SCIENCES | ACCURACY | Reproducibility of Results | Character | Humans | Personality Assessment | Male | Stereotyping | Personality | Ethnic Groups | Cross-Cultural Comparison | Social Perception | Adolescent | Adult | Female | Surveys and Questionnaires | Culture | Research | Social aspects | Analysis | Varieties | Cultural identity | Occupational Therapy | Hälsovetenskap | Medical and Health Sciences | Medicin och hälsovetenskap | Arbetsterapi | Health Sciences
National character studies | Personality traits | Sharks | Southeast Asian culture | Reports | Catholic schools | Slavic culture | Stereotypes | Irish culture | Universities | Personality psychology | STEREOTYPES | MULTIDISCIPLINARY SCIENCES | ACCURACY | Reproducibility of Results | Character | Humans | Personality Assessment | Male | Stereotyping | Personality | Ethnic Groups | Cross-Cultural Comparison | Social Perception | Adolescent | Adult | Female | Surveys and Questionnaires | Culture | Research | Social aspects | Analysis | Varieties | Cultural identity | Occupational Therapy | Hälsovetenskap | Medical and Health Sciences | Medicin och hälsovetenskap | Arbetsterapi | Health Sciences
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 4, pp. 600 - 607
Many previous studies of immune reconstitution (IR) postallogeneic hematopoietic stem cell transplantation (HSCT) have focused on lymphocyte recovery....
Hematology, Oncology and Palliative Medicine | Acute leukemia | Immune reconstitution | Myeloablative | Allogeneic transplant | Monocyte | Lymphocyte | BONE-MARROW-TRANSPLANTATION | SUBSETS | RISK | GRAFT | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | RELAPSE | THERAPY | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGICAL MALIGNANCIES | HEMATOLOGY | T-CELLS | Myeloablative Agonists - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Prognosis | Cell Count | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Monocytes - immunology | Leukemia, Myeloid, Acute - immunology | Graft vs Host Disease - immunology | Transplantation, Homologous | Lymphocytes - immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Time Factors | Monocytes - pathology | Adult | Female | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Lymphocytes - pathology | Adolescent | Myeloablative Agonists - administration & dosage | Transplantation Conditioning | Longitudinal Studies | Cluster Analysis | Medical colleges | Lymphocytes | Analysis | Immunotherapy | Stem cells | Transplantation | Hematopoietic stem cells
Hematology, Oncology and Palliative Medicine | Acute leukemia | Immune reconstitution | Myeloablative | Allogeneic transplant | Monocyte | Lymphocyte | BONE-MARROW-TRANSPLANTATION | SUBSETS | RISK | GRAFT | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | RELAPSE | THERAPY | ACUTE LYMPHOBLASTIC-LEUKEMIA | HEMATOLOGICAL MALIGNANCIES | HEMATOLOGY | T-CELLS | Myeloablative Agonists - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Prognosis | Cell Count | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Monocytes - immunology | Leukemia, Myeloid, Acute - immunology | Graft vs Host Disease - immunology | Transplantation, Homologous | Lymphocytes - immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Time Factors | Monocytes - pathology | Adult | Female | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Graft vs Host Disease - pathology | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Lymphocytes - pathology | Adolescent | Myeloablative Agonists - administration & dosage | Transplantation Conditioning | Longitudinal Studies | Cluster Analysis | Medical colleges | Lymphocytes | Analysis | Immunotherapy | Stem cells | Transplantation | Hematopoietic stem cells
Journal Article
Journal of Clinical Apheresis, ISSN 0733-2459, 06/2018, Volume 33, Issue 3, pp. 324 - 330
In addition to stem cells, T‐cells, natural killer cells, dendritic cells, and monocytes are also collected and infused from the autograft in patients...
autologous graft versus tumor effect | immunologic autograft engineering | survival | MULTIPLE-MYELOMA | EARLY LYMPHOCYTE RECOVERY | PROGRESSION-FREE SURVIVAL | GRAFT | VERSUS-HOST-DISEASE | PROLONGED SURVIVAL | BREAST-CANCER | NON-HODGKIN-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | HEMATOLOGY | PREDICTS SUPERIOR SURVIVAL | Transplantation of organs, tissues, etc | Transplantation | Dendritic cells | Hematopoietic stem cells | Stem cells
autologous graft versus tumor effect | immunologic autograft engineering | survival | MULTIPLE-MYELOMA | EARLY LYMPHOCYTE RECOVERY | PROGRESSION-FREE SURVIVAL | GRAFT | VERSUS-HOST-DISEASE | PROLONGED SURVIVAL | BREAST-CANCER | NON-HODGKIN-LYMPHOMA | HIGH-DOSE CHEMOTHERAPY | HEMATOLOGY | PREDICTS SUPERIOR SURVIVAL | Transplantation of organs, tissues, etc | Transplantation | Dendritic cells | Hematopoietic stem cells | Stem cells
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2015, Volume 90, Issue 4, pp. 334 - 338
Although transformation to Hodgkin lymphoma (HL) is a recognized complication in patients with chronic lymphocytic leukemia (CLL), its incidence, clinical...
RICHTERS-SYNDROME | B-CELL LYMPHOMA | CLL | SCORE | PROGNOSTIC-FACTORS | DISEASE VARIANT | MODERN-ERA | EXPERIENCE | HEMATOLOGY | UTILITY | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Risk Factors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Hodgkin Disease - epidemiology | Leukemia, Lymphocytic, Chronic, B-Cell - complications | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Incidence | Hodgkin Disease - etiology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Hodgkin Disease - drug therapy | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Cell Transformation, Neoplastic - pathology | Databases, Factual | Career development | Complications and side effects | Chronic lymphocytic leukemia | Lymphomas | Analysis
RICHTERS-SYNDROME | B-CELL LYMPHOMA | CLL | SCORE | PROGNOSTIC-FACTORS | DISEASE VARIANT | MODERN-ERA | EXPERIENCE | HEMATOLOGY | UTILITY | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Hodgkin Disease - pathology | Humans | Middle Aged | Risk Factors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Hodgkin Disease - epidemiology | Leukemia, Lymphocytic, Chronic, B-Cell - complications | Leukemia, Lymphocytic, Chronic, B-Cell - epidemiology | Leukemia, Lymphocytic, Chronic, B-Cell - pathology | Incidence | Hodgkin Disease - etiology | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Hodgkin Disease - drug therapy | Female | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Cell Transformation, Neoplastic - pathology | Databases, Factual | Career development | Complications and side effects | Chronic lymphocytic leukemia | Lymphomas | Analysis
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2019, Volume 186, Issue 6, pp. 820 - 828
Summary The diabetes mellitus (DM) drug metformin targets mechanistic/mammalian target of rapamycin and inhibits lymphoma growth in vitro. We investigated...
mTOR | metformin | diabetes mellitus | follicular lymphoma | diffuse large B‐cell lymphoma | EFFICACY | SAFETY | PANCREATIC-CANCER | RISK | diffuse large B-cell lymphoma | INHIBITOR EVEROLIMUS | IDELALISIB | RITUXIMAB | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | ASSOCIATION | Lymphomas | Hypoglycemic agents | Diabetes | Epidemiology | Beta cells | Confidence intervals | TOR protein | Body mass index | Body mass | Diabetes mellitus | Body size | Rapamycin | Metformin | Lymphoma
mTOR | metformin | diabetes mellitus | follicular lymphoma | diffuse large B‐cell lymphoma | EFFICACY | SAFETY | PANCREATIC-CANCER | RISK | diffuse large B-cell lymphoma | INHIBITOR EVEROLIMUS | IDELALISIB | RITUXIMAB | HEMATOLOGY | TYPE-2 DIABETES-MELLITUS | ASSOCIATION | Lymphomas | Hypoglycemic agents | Diabetes | Epidemiology | Beta cells | Confidence intervals | TOR protein | Body mass index | Body mass | Diabetes mellitus | Body size | Rapamycin | Metformin | Lymphoma
Journal Article
American Journal of Hematology, ISSN 0361-8609, 08/2017, Volume 92, Issue 8, pp. 752 - 758
Higher ratios of the pre‐treatment peripheral blood absolute lymphocyte (ALC) to absolute monocyte counts (AMC) are associated with improved outcomes in...
ABSOLUTE MONOCYTE | B-CELL | SOLUBLE IL-2R-ALPHA | HEPATOCYTE GROWTH-FACTOR | NON-HODGKIN-LYMPHOMA | LYMPHOCYTE/MONOCYTE RATIO | FOLLICULAR LYMPHOMA | EOTAXIN RECEPTOR | PROGNOSTIC-SIGNIFICANCE | TO-MONOCYTE RATIO | HEMATOLOGY | Lymphoma - diagnosis | Prognosis | Humans | Middle Aged | Kaplan-Meier Estimate | Lymphoma - immunology | Blood Cells - metabolism | Receptors, Interleukin-2 - metabolism | Male | Combined Modality Therapy | Blood Cells - immunology | Lymphoma - metabolism | Young Adult | Lymphocytes - pathology | Lymphoma - therapy | Monocytes - pathology | Aged, 80 and over | Biomarkers | Adult | Female | Aged | Leukocyte Count | Neoplasm Staging | Cytokines - blood | Care and treatment | Lymphomas | Cytokines | T cells | Leukemia | Immunotherapy
ABSOLUTE MONOCYTE | B-CELL | SOLUBLE IL-2R-ALPHA | HEPATOCYTE GROWTH-FACTOR | NON-HODGKIN-LYMPHOMA | LYMPHOCYTE/MONOCYTE RATIO | FOLLICULAR LYMPHOMA | EOTAXIN RECEPTOR | PROGNOSTIC-SIGNIFICANCE | TO-MONOCYTE RATIO | HEMATOLOGY | Lymphoma - diagnosis | Prognosis | Humans | Middle Aged | Kaplan-Meier Estimate | Lymphoma - immunology | Blood Cells - metabolism | Receptors, Interleukin-2 - metabolism | Male | Combined Modality Therapy | Blood Cells - immunology | Lymphoma - metabolism | Young Adult | Lymphocytes - pathology | Lymphoma - therapy | Monocytes - pathology | Aged, 80 and over | Biomarkers | Adult | Female | Aged | Leukocyte Count | Neoplasm Staging | Cytokines - blood | Care and treatment | Lymphomas | Cytokines | T cells | Leukemia | Immunotherapy
Journal Article
World journal of clinical oncology, ISSN 2218-4333, 11/2010, Volume 1, Issue 1, pp. 29 - 34
The infused stem cell autograft in autologous stem cell transplantation (ASCT) has been viewed mainly as hematologic rescue from the myelosuppressive side...
Autograft | Review | Autologous graft versus tumor effect | Adoptive immunotherapy
Autograft | Review | Autologous graft versus tumor effect | Adoptive immunotherapy
Journal Article
MAYO CLINIC PROCEEDINGS, ISSN 0025-6196, 04/2001, Volume 76, Issue 4, pp. 407 - 412
Autologous hematopoietic stem cell transplantation has proved to be an effective treatment for certain hematologic malignancies. However, relapse rates are...
SYSTEM | INTERLEUKIN-2 | RECOVERY | MEDICINE, GENERAL & INTERNAL | NATURAL-KILLER CELLS | PROGENITOR | BONE-MARROW TRANSPLANTATION | ONTOGENY | NON-HODGKINS-LYMPHOMA | DEPLETION | LEUKEMIA | Hematologic Neoplasms - therapy | Prognosis | Risk Assessment | Hematologic Neoplasms - mortality | Humans | Immunocompetence - immunology | Male | Transplantation Immunology - physiology | Transplantation, Autologous | Treatment Outcome | Hematopoietic Stem Cell Transplantation - mortality | Transplantation, Homologous | Immunocompetence - physiology | Transplantation Immunology - immunology | Sensitivity and Specificity | Survival Analysis | Female | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning
SYSTEM | INTERLEUKIN-2 | RECOVERY | MEDICINE, GENERAL & INTERNAL | NATURAL-KILLER CELLS | PROGENITOR | BONE-MARROW TRANSPLANTATION | ONTOGENY | NON-HODGKINS-LYMPHOMA | DEPLETION | LEUKEMIA | Hematologic Neoplasms - therapy | Prognosis | Risk Assessment | Hematologic Neoplasms - mortality | Humans | Immunocompetence - immunology | Male | Transplantation Immunology - physiology | Transplantation, Autologous | Treatment Outcome | Hematopoietic Stem Cell Transplantation - mortality | Transplantation, Homologous | Immunocompetence - physiology | Transplantation Immunology - immunology | Sensitivity and Specificity | Survival Analysis | Female | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning
Journal Article
Bone marrow research, ISSN 2090-2999, 2013, Volume 2013, pp. 658371 - 8
Day 100 prognostic factors of postautologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcome in classical...
Care and treatment | Patient outcomes | Transplantation | Research | Health aspects | Hodgkin's disease | Hematopoietic stem cells | Clinical Study
Care and treatment | Patient outcomes | Transplantation | Research | Health aspects | Hodgkin's disease | Hematopoietic stem cells | Clinical Study
Journal Article
Immunotherapy, ISSN 1750-743X, 09/2011, Volume 3, Issue 9, pp. 1021 - 1024
VEGF, now increasingly recognized as an immunosuppressant [5], was shown to increase IL-4 and decrease IFN-gγ production by CD4+ T cells in a dose-dependent...
biorhythm | mouse model | angiogenesis | predictive modeling | melanoma | placenta | tolerance | INVASION | IMMUNOLOGY | Neoplasms - therapy | Animals | Melanoma - immunology | Neoplasms - immunology | Humans | Immunotherapy | Mice | Melanoma - therapy | Vascular Endothelial Growth Factor A - physiology | Hypothesis testing | Plasma | Lymphocytes | Mathematical models | Comparative analysis | Vascular endothelial growth factor | Cancer therapies | Cancer | Immune system | Tumors
biorhythm | mouse model | angiogenesis | predictive modeling | melanoma | placenta | tolerance | INVASION | IMMUNOLOGY | Neoplasms - therapy | Animals | Melanoma - immunology | Neoplasms - immunology | Humans | Immunotherapy | Mice | Melanoma - therapy | Vascular Endothelial Growth Factor A - physiology | Hypothesis testing | Plasma | Lymphocytes | Mathematical models | Comparative analysis | Vascular endothelial growth factor | Cancer therapies | Cancer | Immune system | Tumors
Journal Article
BMC Hematology, ISSN 2052-1839, 2014, Volume 14, Issue 1, p. 14
We have previously shown that lymphopenia and monocytopenia at 2-3 months post-allogeneic haematopoietic cell transplant (HCT) is associated with poor survival...
Allogeneic haematopoietic cell transplantation | GVHD | Lymphopenia | Monocytopenia | CMV viraemia
Allogeneic haematopoietic cell transplantation | GVHD | Lymphopenia | Monocytopenia | CMV viraemia
Journal Article
Journal of Clinical Apheresis, ISSN 0733-2459, 2010, Volume 25, Issue 6, pp. 301 - 309
Introduction: Autologous HPC collection focus has been CD34+ cell yield but product content of other cells is important for patient survival, complications,...
granulocytes | multiple myeloma | RBC | platelets | PBSC | Non‐Hodgkin lymphoma | Non-Hodgkin lymphoma | MULTIPLE-MYELOMA | MONONUCLEAR-CELLS | GRAFT | VERSUS-HOST-DISEASE | PBPC TRANSPLANTATION | NON-HODGKINS-LYMPHOMA | 2 SEPARATORS | HEMATOLOGY | RANDOMIZED CROSSOVER | ADVERSE EVENTS | Antigens, CD34 - analysis | Hematopoietic Stem Cells - cytology | Humans | Blood Component Removal - methods | Cell Separation - instrumentation | Lymphocytes - cytology | Cell Separation - methods | Blood Component Removal - instrumentation
granulocytes | multiple myeloma | RBC | platelets | PBSC | Non‐Hodgkin lymphoma | Non-Hodgkin lymphoma | MULTIPLE-MYELOMA | MONONUCLEAR-CELLS | GRAFT | VERSUS-HOST-DISEASE | PBPC TRANSPLANTATION | NON-HODGKINS-LYMPHOMA | 2 SEPARATORS | HEMATOLOGY | RANDOMIZED CROSSOVER | ADVERSE EVENTS | Antigens, CD34 - analysis | Hematopoietic Stem Cells - cytology | Humans | Blood Component Removal - methods | Cell Separation - instrumentation | Lymphocytes - cytology | Cell Separation - methods | Blood Component Removal - instrumentation
Journal Article
Journal of Immunotherapy, ISSN 1524-9557, 07/2010, Volume 33, Issue 6, pp. 618 - 625
Natural antibodies are unique self molecules endowed with both suppressive and activating functions on various cells of the immune system and are recognized as...
Immune reconstitution | TRECs | Naive T lymphocytes | Immunoglobulin | Homeostatic peripheral expansion | MEDICINE, RESEARCH & EXPERIMENTAL | REPERTOIRE | immunoglobulin | DENDRITIC CELLS | EXCISION CIRCLES | BONE-MARROW-TRANSPLANTATION | immune reconstitution | NATURAL ANTIBODIES | RECEPTOR | IMMUNOLOGY | homeostatic peripheral expansion | ONCOLOGY | naive T lymphocytes | INTRAVENOUS IMMUNOGLOBULIN | CARDIAC-SURGERY | IVIG THERAPY | T-Lymphocyte Subsets - immunology | Humans | Immunoglobulins, Intravenous - administration & dosage | Transplantation, Autologous | CD4-Positive T-Lymphocytes - pathology | CD4-Positive T-Lymphocytes - immunology | Lymphopenia - therapy | T-Lymphocyte Subsets - drug effects | Adult | Female | Disease Models, Animal | Receptors, Antigen, T-Cell - metabolism | CD4-Positive T-Lymphocytes - metabolism | Hematopoietic Stem Cell Transplantation | Animals | T-Lymphocyte Subsets - pathology | Thymectomy | T-Lymphocyte Subsets - metabolism | Immunoglobulin Fragments - administration & dosage | Immunologic Memory | Cell Proliferation - drug effects | Lymphopenia - immunology |
Immune reconstitution | TRECs | Naive T lymphocytes | Immunoglobulin | Homeostatic peripheral expansion | MEDICINE, RESEARCH & EXPERIMENTAL | REPERTOIRE | immunoglobulin | DENDRITIC CELLS | EXCISION CIRCLES | BONE-MARROW-TRANSPLANTATION | immune reconstitution | NATURAL ANTIBODIES | RECEPTOR | IMMUNOLOGY | homeostatic peripheral expansion | ONCOLOGY | naive T lymphocytes | INTRAVENOUS IMMUNOGLOBULIN | CARDIAC-SURGERY | IVIG THERAPY | T-Lymphocyte Subsets - immunology | Humans | Immunoglobulins, Intravenous - administration & dosage | Transplantation, Autologous | CD4-Positive T-Lymphocytes - pathology | CD4-Positive T-Lymphocytes - immunology | Lymphopenia - therapy | T-Lymphocyte Subsets - drug effects | Adult | Female | Disease Models, Animal | Receptors, Antigen, T-Cell - metabolism | CD4-Positive T-Lymphocytes - metabolism | Hematopoietic Stem Cell Transplantation | Animals | T-Lymphocyte Subsets - pathology | Thymectomy | T-Lymphocyte Subsets - metabolism | Immunoglobulin Fragments - administration & dosage | Immunologic Memory | Cell Proliferation - drug effects | Lymphopenia - immunology |